SGIOF
Shionogi & Co., Ltd.
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Neutral
-6/100
Last price
17.92
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
17.92
Day high
18.60
Day low
18.60
Volume
10
Market cap
$15.25B
P/E (TTM)
11.20
52W range
14.25 – 26.00
Trailing performance
Returnvs SPY
1W
+9.33%
+7.6%
1M
+1.53%
+0.2%
3M
+0.62%
-2.6%
6M
-20.81%
-35.6%
YTD
+17.82%
+4.0%
1Y
+15.32%
-0.2%
3Y
+23.96%
-57.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SGIOF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
37.53M
Total on file
Fundamentals
Market cap$15.25B
Enterprise value$400.96B
Revenue (TTM)$563.21B
Gross profit$462.28B
EBITDA$150.74B
Net income$263.50B
EPS (TTM)$1.60
Free cash flow$-5.31B
Total cash$298.94B
Total debt$684.13B
Book value / share$13.57
Shares outstanding851.18M
Float850.63M
Short % of float—
Dividend yield2.66%
Beta (5Y)0.07
Valuation & profitability ratios
Trailing P/E11.20
Forward P/E14.45
PEG ratio—
Price / sales—
Price / book1.32
EV / revenue0.71
EV / EBITDA2.66
Gross margin82.08%
Operating margin11.42%
Profit margin46.79%
Return on equity16.77%
Return on assets3.22%
Debt / equity38.59
Current ratio1.14
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $499.68B | $438.27B | $435.08B | $426.68B | +14.0% |
| Operating revenue | $499.68B | $438.27B | $435.08B | $426.68B | +14.0% |
| Cost of revenue | $82.45B | $63.83B | $57.60B | $62.25B | +29.2% |
| Gross profit | $417.23B | $374.44B | $377.48B | $364.44B | +11.4% |
| Research & development | $122.84B | $108.61B | $102.64B | $102.39B | +13.1% |
| Selling, general & admin | $126.91B | $101.87B | $99.65B | $97.78B | +24.6% |
| Total operating expense | $250.50B | $217.84B | $224.17B | $215.43B | +15.0% |
| Operating income | $166.72B | $156.60B | $153.31B | $149.00B | +6.5% |
| Net interest income | $72.19B | $44.15B | $44.97B | $71.33B | +63.5% |
| Pre-tax income | $238.92B | $200.75B | $198.28B | $220.33B | +19.0% |
| Tax provision | $33.00B | $31.21B | $37.71B | $35.84B | +5.7% |
| Net income | $205.16B | $170.44B | $162.03B | $184.97B | +20.4% |
| Net income to common | $205.16B | $170.44B | $162.03B | $184.97B | +20.4% |
| Basic EPS | 241.11 | 200.36 | 186.17 | 207.10 | +20.3% |
| Diluted EPS | 241.04 | 200.29 | 186.11 | 207.03 | +20.3% |
| EBIT | $247.52B | $209.78B | $204.98B | $224.83B | +18.0% |
| EBITDA | $274.49B | $230.71B | $223.31B | $242.00B | +19.0% |
| Basic shares | 850.91M | 850.64M | 870.33M | 893.10M | +0.0% |
| Diluted shares | 851.13M | 850.94M | 870.63M | 893.41M | +0.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $711.40B | $374.80B | $358.09B | $309.22B | +89.8% |
| Cash & short-term investments | $1.02T | $644.82B | $573.85B | $563.36B | +58.5% |
| Accounts receivable | $159.77B | $120.55B | $122.83B | $109.77B | +32.5% |
| Inventory | $99.40B | $65.48B | $64.92B | $57.92B | +51.8% |
| Total current assets | $1.31T | $858.50B | $784.21B | $784.19B | +52.6% |
| Property, plant & equipment | $179.31B | $134.81B | $124.03B | $118.57B | +33.0% |
| Goodwill & intangibles | $208.61B | $159.40B | $132.91B | $106.13B | +30.9% |
| Total assets | $2.58T | $1.54T | $1.42T | $1.31T | +67.8% |
| Total current liabilities | $827.43B | $129.39B | $133.91B | $158.55B | +539.5% |
| Current debt | $660.00B | $0 | — | — | — |
| Total debt | $684.39B | $21.88B | $11.62B | $9.41B | +3,027.7% |
| Total liabilities | $890.67B | $172.85B | $164.36B | $189.92B | +415.3% |
| Retained earnings | $1.49T | $1.12T | $1.07T | $940.61B | +33.8% |
| Shareholder equity | $1.69T | $1.36T | $1.24T | $1.10T | +23.7% |
| Working capital | $482.90B | $729.11B | $650.30B | $625.64B | -33.8% |
| Net tangible assets | $1.48T | $1.20T | $1.10T | $993.92B | +22.8% |
| Shares issued | 889.63M | 889.63M | 922.16M | 922.16M | 0.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | $238.92B | $200.75B | $198.28B | $220.33B | +19.0% |
| Depreciation & amortisation | $26.97B | $20.93B | $18.32B | $17.16B | +28.8% |
| Change in working capital | -$8.28B | -$181.00M | -$24.53B | $9.98B | -4,476.2% |
| Operating cash flow | $213.57B | $195.46B | $154.28B | $177.87B | +9.3% |
| Capital expenditure | -$31.30B | -$52.10B | -$28.27B | -$37.19B | +39.9% |
| Investing cash flow | -$506.14B | -$116.08B | $5.92B | -$48.29B | -336.0% |
| Share buybacks | -$5.00M | -$10.00M | -$75.18B | -$49.54B | +50.0% |
| Dividends paid | -$56.17B | -$48.70B | -$43.88B | -$36.14B | -15.4% |
| Financing cash flow | $599.32B | -$64.91B | -$126.85B | -$84.12B | +1,023.3% |
| Free cash flow | $182.27B | $143.36B | $126.02B | $140.68B | +27.1% |
| End cash position | $711.40B | $374.80B | $358.09B | $309.22B | +89.8% |
| Line item | 2026-06-30 | 2025-06-30 | YoY |
|---|---|---|---|
| Basic EPS | 114.81 | — | — |
| Diluted EPS | 114.78 | 46.25 | +148.2% |
| Basic shares | 850.98M | — | — |
| Diluted shares | 851.16M | — | — |
| Line item | 2026-03-31 | 2025-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $711.40B | $374.80B | +89.8% |
| Cash & short-term investments | $1.02T | $644.82B | +58.5% |
| Accounts receivable | $159.77B | $120.55B | +32.5% |
| Inventory | $99.40B | $65.48B | +51.8% |
| Total current assets | $1.31T | $858.50B | +52.6% |
| Property, plant & equipment | $179.31B | $134.81B | +33.0% |
| Goodwill & intangibles | $208.61B | $159.40B | +30.9% |
| Total assets | $2.58T | $1.54T | +67.8% |
| Total current liabilities | $827.43B | $129.39B | +539.5% |
| Current debt | $660.00B | $0 | — |
| Total debt | $684.39B | $21.88B | +3,027.7% |
| Total liabilities | $890.67B | $172.85B | +415.3% |
| Retained earnings | $1.49T | $1.12T | +33.8% |
| Shareholder equity | $1.69T | $1.36T | +23.7% |
| Working capital | $482.90B | $729.11B | -33.8% |
| Net tangible assets | $1.48T | $1.20T | +22.8% |
| Shares issued | 889.63M | 889.63M | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $175.38B | +54.9% |
| Next quarter | — | — | $188.12B | +27.4% |
| Current year | — | — | $710.78B | +82.9% |
| Next year | — | — | $742.18B | +4.4% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders4.41%
Held by institutions55.36%
Institutions holding362
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
16.95
+5.70% from price
SMA 20
17.30
+3.57% from price
SMA 50
17.71
+1.18% from price
SMA 100
17.75
+0.94% from price
SMA 200
18.86
-5.00% from price
EMA 12
17.17
+4.35% from price
EMA 26
17.38
+3.13% from price
EMA 50
17.61
+1.77% from price
RSI (14)
61.4
Neutral
MACD (12,26,9)
-0.20
Hist 0.07
ATR (14)
0.20
1.11% of price
Realised vol 30D
38.4%
Annualised
Bollinger upper
18.49
20, 2σ
Bollinger lower
16.11
20, 2σ
50 / 200 cross
Death
17.71 vs 18.86
Trend bias
Below 200
-5.00%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.15
Less volatile than market
Correlation to SPY
0.03
Largely independent
Realised vol 30D
38.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-38.5%
Peak to trough
Max drawdown 5Y
-73.2%
Peak to trough
ATR 14
0.20
1.11% of price
Beta (reported)
0.07
5Y monthly, from filing
Dividends & splits
Forward rate$0.48 / yr
Forward yield2.66%
5-year avg yield2.13%
Payout ratio29.46%
Ex-dividend dateMar 30, 2027
Next pay dateJun 21, 2018
Last split3:1
Split dateSep 27, 2024
Headlines
Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout
Pharmaceutical Technology · 1d ago
Shionogi acquires rare disease startup IntraBio for $2 billion
Quartz · 2d ago
Shionogi pays $2B to acquire a rare disease startup
BioPharma Dive · 2d ago
Shionogi Continues Rare Disease Expansion With Planned Acquisition of IntraBio Inc.
Business Wire · 2d ago
Interest Rate Outlook Lifts Asian Stock Markets
MT Newswires · 2d ago
Shionogi to Acquire IntraBio for $2 Billion
The Wall Street Journal · 2d ago
Celaid Therapeutics Completes Second Close of Series B Financing Round
PR Newswire · 3d ago
Shionogi & Co Ltd's Dividend Analysis
GuruFocus.com · 8d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.